Chiesi Invests Heavily in Gossamer’s Promising Pulmonary Hypertension Treatment

1. Chiesi Farmaceutici S.p.A., an international research-focused healthcare group, has announced a significant investment in Gossamer Bio Inc., a clinical-stage biopharmaceutical company. The deal is worth up to $486 million, including an upfront payment, development and commercial milestones, and royalties.
2. The investment focuses on Gossamer's lead product candidate, GD-001, which is currently in Phase 2 clinical trials for the treatment of pulmonary arterial hypertension (PAH), a rare and life-threatening cardiovascular disease.
3. GD-001 is a potential first-in-class treatment that targets the prostacyclin pathway, a well-established mechanism for treating PAH. It is designed to improve efficacy and tolerability compared to existing prostacyclin therapies.
4. Chiesi and Gossamer will collaborate on the development and commercialization of GD-001, with Chiesi leading commercialization efforts in the United States and Gossamer retaining commercial rights outside the U.S.
5. The collaboration aims to address the unmet medical needs of patients with PAH, a condition characterized by high blood pressure in the arteries of the lungs, which can lead to heart failure and death.
6. Chiesi has a strong track record in the cardiovascular space, with a focus on developing and commercializing innovative treatments for rare and chronic diseases. This investment in Gossamer's GD-001 aligns with Chiesi's commitment to improving patient outcomes in this therapeutic area.
7. The deal is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Upon closing, Chiesi will make an upfront payment to Gossamer and will be eligible to receive milestone payments and royalties based on the successful development and commercialization of GD-001.